Secukinumab Therapy in Psoriasis Management

Background : In recent years, use of biological therapy in psoriasis has increased as a result of advances in understanding the pathophysiology of psoriasis disease. Biological agents currently approved for the treatment of moderate to severe plaque psoriasis including inhibitor TNF-α (adalimumab, e...

Full description

Bibliographic Details

Published in:	Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology)
Main Authors:	Ira Yunita, Sylvia Anggraeni
Format:	Article
Language:	Indonesian
Published:	Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga 2022-03-01
Subjects:	psoriasis biologic agents inhibitor il-17 secukinumab human & disease
Online Access:	https://e-journal.unair.ac.id/BIKK/article/view/20013